The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
Status:
Not yet recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase
II clinical study to evaluate the efficacy and safety of F520 for the treatment of relapsed
and refractory peripheral T cell lymphoma (PTCL), and to evaluate the immunogenicity of F520.